Novartis AG Announces Groundbreaking $1.7B Acquisition of Regulus Therapeutics to Revolutionize ADPKD Treatment

Novartis AG is set to acquire Regulus Therapeutics in a deal worth up to $1.7B, aiming to advance the treatment for ADPKD through the development of farabursen, with the transactio...